{
    "root": "72579e23-23ef-4ab7-ad64-24d5ea7997eb",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Pravastatin Sodium",
    "value": "20240101",
    "ingredients": [
        {
            "name": "PRAVASTATIN SODIUM",
            "code": "3M8608UQ61",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_8361"
        },
        {
            "name": "ANHYDROUS DIBASIC CALCIUM PHOSPHATE",
            "code": "L11K75P92J",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_77635"
        },
        {
            "name": "CROSPOVIDONE (15 MPA.S AT 5%)",
            "code": "68401960MK"
        },
        {
            "name": "ANHYDROUS LACTOSE",
            "code": "3SY5LH9PMK",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_17716"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X",
            "drugbank_id": "https://go.drugbank.com/drugs/DB14478"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "SODIUM STEARYL FUMARATE",
            "code": "7CV7WJK4UI",
            "drugbank_id": "https://go.drugbank.com/drugs/DB00815"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_50819"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "D&C YELLOW NO. 10",
            "code": "35SW5USQ3G"
        }
    ],
    "indications": {
        "text": "pravastatin sodium tablets indicated : reduce risk myocardial infarction , myocardial revascularization procedures , cardiovascular mortality adults elevated low-density lipoprotein cholesterol ( ldl-c ) without clinically evident coronary heart disease ( chd ) . reduce risk coronary death , myocardial infarction , myocardial revascularization procedures , stroke transient ischemic attack , slow progression coronary atherosclerosis adults clinically evident chd . adjunct diet reduce ldl-c adults primary hyperlipidemia . adjunct diet reduce ldl-c pediatric patients ages 8 years older heterozygous familial hypercholesterolemia ( hefh ) . adjunct diet treatment adults : primary dysbetalipoproteinemia . hypertriglyceridemia .",
        "doid_entities": [
            {
                "text": "myocardial infarction (DOID:5844)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_5844"
            },
            {
                "text": "coronary heart disease (DOID:3393)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_3393"
            },
            {
                "text": "heart disease (DOID:114)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_114"
            },
            {
                "text": "disease (DOID:4)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4"
            },
            {
                "text": "stroke (DOID:6713)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_6713"
            },
            {
                "text": "transient ischemic attack (DOID:224)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_224"
            },
            {
                "text": "coronary atherosclerosis (DOID:0061139)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_0061139"
            },
            {
                "text": "atherosclerosis (DOID:1936)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1936"
            },
            {
                "text": "familial hypercholesterolemia (DOID:13810)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_13810"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "take orally daily time day , without food ( 2.1 ) . patients require high-intensity statin unable achieve ldl-c goal receiving pravastatin sodium tablets 80 mg daily , prescribe alternative ldl-c-lowering treatment ( 2.1 ) . assess ldl-c clinically appropriate , early 4 weeks initiating pravastatin sodium tablets , adjust necessary ( 2.1 ) . adults : recommended starting pravastatin sodium tablets 40 mg 80 mg daily . ( 2.2 ) pediatric patients ( 2.3 ) : aged 8 13 years , recommended 20 mg daily . aged 14 18 years , recommended starting 40 mg daily . severe renal impairment : recommended starting pravastatin sodium 10 mg daily . another pravastatin sodium product initiate dosing . recommended maximum pravastatin sodium tablets 40 mg daily . ( 2.4 ) full prescribing information modifications due ( 2.5 , 7 ) .",
        "doid_entities": [],
        "orphanet_entities": [
            {
                "disease": "severe renal impairment",
                "orphanet_id": "http://www.orpha.net/ORDO/Orphanet_447788"
            }
        ]
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "acute liver failure decompensated cirrhosis [ ( 5.3 ) ] . hypersensitivity pravastatin excipients pravastatin sodium tablets .",
    "indications_original": "Pravastatin sodium tablets are indicated:\n                  \n                     To reduce the risk of myocardial infarction, myocardial revascularization procedures, and cardiovascular mortality in adults with elevated low-density lipoprotein cholesterol (LDL-C) without clinically evident coronary heart disease (CHD).\n                     To reduce the risk of coronary death, myocardial infarction, myocardial revascularization procedures, stroke or transient ischemic attack, and slow the progression of coronary atherosclerosis in adults with clinically evident CHD.\n                     As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia.\n                     As an adjunct to diet to reduce LDL-C in pediatric patients ages 8 years and older with heterozygous familial hypercholesterolemia (HeFH).\n                     As an adjunct to diet for the treatment of adults with:\n                           Primary dysbetalipoproteinemia.\n                           Hypertriglyceridemia.",
    "contraindications_original": "Take orally once daily at any time of the day, with or without food ( 2.1 ). For patients that require a high-intensity statin or are unable to achieve their LDL-C goal receiving pravastatin sodium tablets 80 mg daily, prescribe alternative LDL-C-lowering treatment ( 2.1 ). Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating pravastatin sodium tablets, and adjust the dosage if necessary ( 2.1 ). Adults: recommended starting dosage is pravastatin sodium tablets 40 mg to 80 mg once daily. ( 2.2 ) Pediatric Patients ( 2.3 ): aged 8 to 13 years, the recommended dosage is 20 mg once daily. aged 14 to 18 years, the recommended starting dosage is 40 mg once daily. Severe renal impairment: recommended starting dosage is pravastatin sodium 10 mg once daily. Use another pravastatin sodium product to initiate dosing. Recommended maximum pravastatin sodium tablets dosage is 40 mg once daily. ( 2.4 ) See full prescribing information for dosage modifications due to drug interactions ( 2.5 , 7 ).",
    "adverseReactions_original": "Acute liver failure or decompensated cirrhosis [see Warnings and Precautions (5.3)].\n                     \n                     Hypersensitivity to any pravastatin or any excipients in pravastatin sodium tablets.",
    "drug": [
        {
            "name": "Pravastatin Sodium",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_8361"
        }
    ]
}